H. Lundbeck AS - Company Profile

Powered by

All the data and insights you need on H. Lundbeck AS in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date H. Lundbeck AS Strategy Report

  • Understand H. Lundbeck AS position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

H. Lundbeck AS: Overview

Select Item

Related keylists

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, migraine, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

 Gain a 360-degree view of H. Lundbeck AS and make more informed decisions for your business Gain a 360-degree view of H. Lundbeck AS and make more informed decisions for your business Find out more
Headquarters Denmark
Address Ottiliavej 9, Valby, 2500
Website www.lundbeck.com
Telephone 45 36301311
No of Employees 5,681
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange HLUN A (CPH)
Revenue (2022) $2.9B 9.1% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 19.5% (2022 vs 2021)
Market Cap* $4.5B
Net Profit Margin (2022) XYZ 9.5% (2022 vs 2021)
* As of and is in US$
View H. Lundbeck AS financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

H. Lundbeck AS premium industry data and analytics

540+

Clinical Trials

Determine H. Lundbeck AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

120+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for H. Lundbeck AS’s relevant decision makers and contact details.

110+

Catalyst Calendar

Proactively evaluate H. Lundbeck AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

100+

Pipeline Drugs

Identify which of H. Lundbeck AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

70+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Marketed Drugs

Understand H. Lundbeck AS’s commercialized product portfolio to stay one step ahead of the market.

14+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

13+

Sales & Consensus Forecasts

Understand the current and future drug revenue for H. Lundbeck AS and assess market opportunity for new entrants with patient population 8-year forecasts.

4

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for H. Lundbeck AS (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

Products and Services

Products Brands
Pharmaceuticals: Ebixa
Disease Areas: Azilect
Alzheimer's Disease Serdolect
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand H. Lundbeck AS portfolio and identify potential areas for collaboration Understand H. Lundbeck AS portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Regulatory Approval In March, the company received approval for Abilify Maintena 960 mg (aripiprazole) from the European Commission (EC).
2023 Contracts/Agreements In July, Lundbeck Export entered into a partnership with Bora Pharmaceuticals under which Bora will be responsible for sales and marketing of Lundbeck’s products through Bora’s specialized hospital, clinic, and drug store channels in Taiwan.
2023 Contracts/Agreements In May, the company collaborated with Alloy Therapeutics for discovery of novel biologics therapies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters H. Lundbeck AS Novo Nordisk AS Viatris Inc Orifarm Group A/S Leo Pharma AS
Headquarters Denmark Denmark United States of America Denmark Denmark
City Valby Bagsvaerd Canonsburg Odense Ballerup
State/Province - - Pennsylvania - -
No. of Employees 5,681 63,370 38,000 2,316 5,252
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Lars Soren Rasmussen Chairman Executive Board 2018 65
Charl van Zyl President; Chief Executive Officer Senior Management 2023 57
Joerg Hornstein Chief Financial Officer; Executive Vice President - Corporate Functions Senior Management 2022 47
Lene Skole-Sorensen Deputy Chairman Executive Board 2015 65
Per Johan Luthman, Ph.D. Executive Vice President - Research and Development Senior Management 2019 65
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into H. Lundbeck AS key executives to enhance your sales strategy Gain insight into H. Lundbeck AS key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward